Docking Studies and Molecular Dynamics Simulation of Compounds Contained in Kaempferia Galanga L. to Lipoxygenase (LOX) for Anti-Inflammatory Drugs by Supandi et al.
 
J. Math. Fund. Sci. Vol. 53, No. 2, 2021, 218-230                     218 
 
 
Received August 7th, 2020, Revised February 28th, 2021, Accepted for publication August 15th, 2021. 
Copyright © 2021 Published by ITB Institute for Research and Community Services, ISSN: 2337-5760, 
DOI: 10.5614/j.math.fund.sci.2021.53.2.4 
Docking Studies and Molecular Dynamics Simulation of 
Compounds Contained in Kaempferia Galanga L. to 
Lipoxygenase (LOX) for Anti-Inflammatory Drugs 
Supandi, Yeni* & Lusi Putri Dwita 
Pharmacy Department, Faculty of Pharmacy and Science, Universitas Muhammadiyah 




Abstract. Inflammation is a self-protective response to start the healing process. 
An anti-inflammatory target worth developing are lipoxygenase inhibitors, which 
have been studied for several diseases, including severe respiratory disease. This 
research had the goals of estimating the activity of 21 compounds from K. 
galanga to inhibit the lipoxygenase (LOX) and estimating the bond stability of 
the ligand-LOX complex. Based on the compound’s affinity for LOX, the 
compounds in K. galanga were selected by utilizing the PLANTS docking 
software, with zileuton as the reference ligand. The GROMACS application was 
used to simulate the molecular dynamics of the LOX-ligand complex at 310 K. 
Based on the chemPLP score, most of the 21 K. galanga compounds showed a 
higher affinity towards 5-LOX compared to zileuton. δ-3-carene had the best 
affinity for 5-LOX. In the simulation of molecular dynamics until 20 ns, the 
RMSD of δ-3-carene and 5-LOX was not more than 0.03 nm or 0.3 Å, indicating 
that the whole system showed decent stability and had -1.67392 x 106 kcal/mol 
as the average potential energy. The results showed that K. galanga contains 
active components of 5-LOX inhibitors that could be developed.  
Keywords: anti-inflammatory; docking; Kaempferia galanga L.; lipoxygenase; 
molecular dynamics. 
1 Introduction 
Kaempferia galanga rhizome is used as a raw material in the traditional 
medicine industry, especially in Indonesia. It has several functions, for example 
in the treatment of inflammation as an analgesic, antioxidant, sedative, 
antimicrobial and even as antineoplastic agent [1]. Essential oil 2.5-4% in the 
rhizome of K. galanga consists of ethyl cinnamate (25%), ethyl p-
methoxycinnamic (30%), p-methoxycinnamic acid, monoterpenes ketone, and 
3-carene-5-one. The other compounds are camphene, δ-3-carene, p-methoxy 
styrene, γ-pinene, β-myrcene, p-cymene, 1,8-cineole, iso-myrcene, camphor, α-
terpineol, p-cymene- 8-ol, eucarvone and δ-cadinene. Some compounds, such as 
kaempferol, quercetin, cyanidin and delphinidin, can be found in the leaves of 
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K. galanga [2]. K. galanga has shown potential in inhibiting cyclooxygenase 
and TNF-alpha [3], and possibly could also bind to lipoxygenase enzyme 
because of the active site pockets in cyclooxygenase-2 (COX-2) and 5-
lipoxygenase (5-LOX) located near cofactors (Fe2+ in 5-LOX or Hem in COX-
2). Nevertheless, the single hydrogen bonds in the interaction of α-amyrins with 
COX-2 and 5-LOX are formed at the different amino acid residues GLN290 of 
COX-2 and ASN554 of LOX-5 besides hydrophobic interactions [4]. Anti-
inflammatory research has been carried out in vitro against isolates of K. 
galanga such as isopimarane diterpenoids [3]. 
Lipoxygenases (LOX) is an oxido-reductase enzyme. Single-electron oxidation 
by iron atom switching between the redox states of Fe2+ and Fe3+ occurs in the 
LOX catalytic reaction. Arachidonic acid is first oxygenated on the fifth carbon 
by 5-LOX in conjunction with its activating protein, 5-lipoxygenase-activating 
protein (FLAP), to give 5-hydroperoxy eicosatetraenoic acid (5-HPETE). 5-
LOX, with FLAP, and then catalyzes a second step, the dehydration of 5-
HPETE to leukotriene [5]. 
There are two types of drugs for the treatment of inflammation, non-steroidal 
anti-inflammatory drugs (NSAIDs) and corticosteroids [6]. Systemic 
corticosteroids have an integral role in managing inflammatory and 
immunological conditions. However, these drugs cause serious side effects 
especially when used at high doses for a long time against conditions such as 
osteoporosis, adrenal suppression, hyperglycemia, dyslipidemia, cardiovascular 
disease, Cushing’s syndrome, psychiatric disorders, and immunosuppression 
[7]. Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to reduce pain 
and inflammation. Based on the level of selectivity for COX inhibition there are 
two types of NSAIDs, non-selective and COX-2-selective inhibitors (COXIBS) 
[8]. Long-term use of NSAIDs causes side effects on the gastrointestinal, renal 
and cardiovascular systems [9]. 
Zileuton is a drug that can inhibit 5-LOX, an initial enzyme in the leukotriene 
pathway. Zileuton is marketed for asthma treatment. This drug has limited 
clinical use because of its hepatotoxicity [10]. Therefore, new drugs are needed 
that have greater anti-inflammatory activity and fewer side effects than existing 
anti-inflammatory drugs. Zileuton could be used as a reference in 5-LOX 
inhibitors studies. 
Virtual screening and drug design optimization have been conducted by 
molecular docking, a method in computer-aided drug design (CADD) [11]. The 
physical properties of the structure and how the biological macromolecules 
function can be discovered through molecular dynamics simulation [12], 
producing root mean square deviation (RMSD) graphs, root mean square 
fluctuations (RMSF), and potential energy [13][14]. Several docking studies 
have been conducted to obtain novel 5-LOX inhibitors, for example docking 
studies of thiazolyl derivatives [15], diospyrin [16] and coumaperine derivatives 
[17]. This study conducted molecular dynamic simulations of K. galanga 
compounds as LOX-inhibitor.  
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2 Materials and Methods 
The docking studies in the present study were conducted using the software 
PLANTS (Protein-Ligand ANT System [18]. The compounds in K. galanga and 
zileuton in a 3D structure were docked to 5-LOX as receptor. The 3D structure 
of 5-LOX was downloaded from the Protein Data Bank (PDB) with a resolution 
of 2.07 Å, PDB code 3V98 [19]. The 5-LOX enzyme was separated from Fe2+ 
ion previously using YASARA (Yet Another Scientific Artificial Reality 
Application). First, method validation was carried out by redocking Fe2+ to the 
receptor with the requirement that the RMSD value was not more than 2 Å [20]. 
Marvin Sketch transformed the 3D structure of ligands that are available in 
PubChem into 2D form. Scanning of the process of protonation was carried out 
by adjusting the pH to 7.4. The YASARA application was used to find the 
ligand conformation with the lowest energy before proceeding to molecular 
docking [18]. The Chemical Piecewise Linear Potential (ChemPLP) scores were 
obtained from the docking result. A more negative value of the ChemPLP score 
indicates higher affinity of the compound’s bond with the receptor. 
Visualization of the molecular docking results was performed using Discovery 
Studio. The compound selected to proceed to the molecular dynamic simulation 
stage was the compound with the most negative ChemPLP score. 
Molecular dynamic simulations were carried out using GROMACS (Groningen 
Machine for Chemical Simulations) on the compound-receptor complex that 
was selected in the previous stage. The coordinates of this complex were 
x = 9.08400 Å, y = 12.12800 Å and z = 11.20300 Å. In the molecular dynamic 
simulation, the LINCS (Linear Constraint Solver) algorithm was used in the 
AMBER99SB-ILDN ((Assisted Model Building with Energy Refinement) 
99SB side-chain dihedral) force field. Molecular dynamics simulation was 
conducted for 20 ns with temperature at 310 K. The analytical parameters of the 
simulation were RMSD (root mean square deviation), RMSF (root mean square 
fluctuations), and potential energy. The molecular dynamics simulation result 
was visualized using VMD [21]. 
Figure 1 5-lipoxygenase enzyme with Fe2+ ion from PDB. 
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3 Results and Discussion 
3.1 Data Collection 
In this study, 21 compounds of K. galanga flavonoids that have anti-
inflammatory potential were studied for their activity against the lipoxygenase 
enzyme. The receptor was the 5-lipoxygenase enzyme with Fe2+ ion (Figure 1) 
[19]. 
The drug used as reference ligand was zileuton, which is a 5-lipoxygenase (5-
LOX) inhibitor. It is used in asthma treatment and can be used as a selective 
tool for evaluation of 5-LOX and leukotriene function [22][23]. 
Zileuton has been studied for various diseases, such as myocardial infarction, 
non-alcoholic fatty liver disease, and severe respiratory disease [24]-[28]. In 
PubChem, the 3D structure of the compounds in K. galanga and zileuton were 
obtained (Table 1) [24]. 
Table 1 PubChem CID Data of Zileuton and Compounds Contained in K. galanga L. 
No Compound PubChem CID No Compound PubChem CID 
1 Zileuton 60490 12 1,8-cineole 2758 
2 Ethyl cinnamate 637758 13 Iso-myrcene 519324 
3 Ethyl p-methoxycinnamic 5281783 14 Camphor 2537 
4 p-methoxycinnamic acid 699414 15 α-terpineol 17100 
5 3-carene-5-one 10057675 16 p-cymene-8-ol 7463 
6 Camphene 6616 17 Eucarvone 136330 
7 δ-3-carene 442461 18 δ-cadinene 12306054 
8 p-methoxy styrene 12507 19 Kaempferol 5280863 
9 γ-pinene 6431006 20 Quercetin 5280343 
10 β-myrcene 31253 21 Cyanidin 128861 
11 p-cymene 7463 22 Delphinidin 128853 
3.2 Docking Study 
Docking studies are part of computational chemistry and can be carried out to 
understand the interactions that occur between ligands and their receptors, 
which can predict the bonding association [29]. Docking studies can recognize 
molecules by finding the active sites on the ligand and the receptor that bind to 
each other, predicting the binding affinity [30]. Molecular docking in this study 
was carried out using PLANTS for compounds contained in K. galanga and 
zileuton as reference ligand. PLANTS applies the flexible docking method, i.e. 
the receptor and the ligand are in a flexible state in the docking process [29]-
[31]. 
Before beginning the docking study, method validation and redocking were 
carried out using PLANTS with Fe2+ ion in order to find out the reliability of the 
docking protocol. The coordinates of the receptor binding sites were obtained 
by redocking. These coordinates were used as the default receptor binding sites 
in the virtual screening for 21 compounds of K. galanga and zileuton [32]. The 
result of redocking 5-LOX with Fe2+ ion produced an RMSD value of 0 Å. The 
docking method with PLANTS software for 5-LOX as receptor was applicable 
222 Supandi, et al. 
in this research because the RMSD value of the molecular docking method 
validation <2 Å [13]. 
The results are displayed as chemPLP score, which is an empirical fitness 
function that is optimized for predicting purposes. Among all 21 compounds, 
the highest affinity was shown by δ-3-carene with the lowest chemPLP score, 
20.0002 kcal/mol (Figure 2, Table 2), i.e. higher affinity compared to zileuton. 
There are 12 hydrophobic bonds between δ-3-carene and 5-lipoxygenase. δ-3-
carene and zileuton bind to the same amino acid residue valine 671 in 5-LOX. 
The interaction types are hydrophobic. 






Bond Type Binding Site 







:UNK*:N2 - :ILE673:O 
:UNK:H2 - :SER670:O 
:UNK:C6 - :VAL553 
:HIS367 - :UNK:C6 
:UNK - :VAL374 
:UNK - :VAL671 
2 Ethyl cinnamate -19.9983 
Hydrogen Bond 
Hydrophobic 
:UNK:H5 - :PHE151:O 
:UNK:C5 - :ARG518 











:ARG411:HH12 - :UNK:O3 
:UNK:H7 - :THR403:O 
:UNK:H8 - :HIS372:O 
:UNK:C12 - :ILE415 
:TRP147 - :UNK:C12 
:PHE151 - :UNK:C12 
:HIS372 - :UNK:C9 
:UNK - :LEU368 
:UNK - :LEU373 
:UNK - :ILE415 





:ARG370:H - :UNK:O1 
:UNK:H7 - :ILE365:O 
:UNK:C9 - :ARG370 
:UNK:C9 - :VAL553 






:UNK - :LEU443 
:UNK - :LEU448 
:UNK:C5 - :LEU369 
:UNK:C5 - :ARG370 
:UNK:C5 - :VAL374 
Figure 2 Docking result visualization of δ-3-carene with 5-lipoxygenase 
complex. δ-3-carene forms 12 hydrophobic bonds with 5-lipoxygenase on 
the amino acid residues valine 671, alanine 546, histidine 367, histidine 372 
and histidine 550. 











:UNK:C6 - :VAL374 
:UNK:C6 - :LEU448 
:UNK:C6 - :MET517 
:PHE525 - :UNK:C6 















:PRO152 - :UNK 
:MET517 - :UNK 
:ARG518 - :UNK 
:ARG518 - :UNK 
:UNK - :PRO152 
:UNK - :MET440 
:UNK - :MET517 
:UNK:C8 - :MET440 
:UNK:C8 - :MET517 
:UNK:C9 - :PRO152 
:UNK:C9 - :MET440 
:UNK:C10 - :PRO152 
:UNK:C10 - :LEU443 
:UNK:C10 - :MET517 













:UNK - :VAL671 
:UNK:C6 - :VAL671 
:UNK:C7 - :VAL671 
:UNK:C10 - :ALA546 
:ALA546 - :UNK 
:HIS367 - :UNK 
:HIS367 - :UNK:C6 
:HIS367 - :UNK:C7 
:HIS372 - :UNK 
:HIS372 - :UNK:C7 
:HIS550 - :UNK 
:HIS550 - :UNK:C6 








:HIS367:HD1 - :UNK:O1 
:UNK:C8 - :LEU414 
:UNK:C8 - :LEU607 
:HIS367 - :UNK:C8 
:HIS432 - :UNK:C9 
:UNK - :LEU368 
:UNK - :LEU414 


















:PRO152 - :UNK 
:ILE365 - :UNK 
:VAL436 - :UNK 
:VAL436 - :UNK 
:ALA439 - :UNK 
:ALA439 - :UNK 
:ALA439 - :UNK:C10 
:MET440 - :UNK 
:UNK - :MET440 
:UNK - :LEU443 
:UNK:C7 - :ILE365 
:UNK:C7 - :VAL436 
:UNK:C8 - :LEU373 
:UNK:C8 - :VAL436 
:UNK:C10 - :LEU369 
:UNK:C10 - :MET440 
:UNK:C10 - :LEU443 





:UNK - :LEU373 
:UNK:C6 - :MET145 
:UNK:C9 - :LEU373 
:UNK:C10 - :LEU373 





Bond Type Binding Site 
Hydrophobic 
Hydrophobic 
:TRP147 - :UNK:C6 
:TRP147 - :UNK:C6 





:UNK:C1 - :LEU443 
:UNK:C10 - :VAL374 
:UNK:C10 - :VAL377 
:UNK - :VAL377 













:ARG520:HE - :UNK:O1 
:ARG520:HH21 - :UNK:O1 
:LEU369 - :UNK 
:LEU443 - :UNK 
:MET517 - :UNK 
:UNK - :PRO152 
:UNK - :LEU369 
:UNK - :LEU443 
:UNK:C9 - :LEU443 
:UNK:C10 - :MET440 
:UNK:C10 - :LEU443 
:UNK:C10 - :MET517 








:UNK:C9 - :LEU369 
:UNK:C9 - :ARG370 
:UNK:C10 - :VAL553 
:HIS367 - :UNK 
:HIS367 - :UNK:C6 
:HIS367 - :UNK:C10 
:HIS372 - :UNK:C6 






:VAL436 - :UNK 
:UNK:C8 - :VAL433 
:UNK:C8 - :VAL436 
:PHE151 - :UNK:C8 
:PHE151 - :UNK:C9 












:LEU368 - :UNK 
:VAL433 - :UNK 
:UNK:C8 - :ILE365 
:UNK:C8 - :LEU368 
:UNK:C8 - :LEU369 
:UNK:C9 - :MET435 
:UNK:C9 - :VAL436 
:UNK:C10 - :VAL433 
:TRP147 - :UNK:C10 
:HIS432 - :UNK 
:HIS432 - :UNK:C9 










:UNK:C3 - :LEU368 
:UNK:C4 - :LEU607 
:UNK:C10 - :ILE406 
:UNK:C10 - :LYS409 
:HIS367 - :UNK:C3 
:HIS367 - :UNK:C4 
:HIS372 - :UNK:C3 
:HIS372 - :UNK:C4 
:UNK - :ALA410 









:PRO152 - :UNK 
:VAL374 - :UNK 
:UNK:C3 - :VAL512 
:UNK:C3 - :MET517 
:UNK:C4 - :MET517 
:UNK:C10 - :VAL374 
:UNK:C10 - :LEU448 
:UNK:C10 - :MET517 










:TRP144 - :UNK:C3 
:PHE378 - :UNK:C10 
:PHE525 - :UNK:C10 









:LEU368 - :UNK 
:UNK:C5 - :LEU373 
:UNK:C5 - :ARG411 
:UNK:C14 - :LEU373 
:UNK:C15 - :LEU373 
:TRP147 - :UNK:C5 
:TRP147 - :UNK:C5 
:HIS372 - :UNK:C15 






:ARG411:HH11 - :UNK:O1 
:ARG411:HH12 - :UNK:O1 
:UNK:O2 - :LEU373:O 
:ARG411:NH2 - :UNK 
:GLU376:OE2 - :UNK 





:ILE155:HN - :UNK:O6 
:TRP147 - :UNK 
:TRP147 - :UNK 
:UNK - :LEU373 







:UNK:H7 - :HIS432:O 
:VAL436:HA - :UNK:O3 
:LEU369:HN - :UNK 
:UNK - :ILE365 
:UNK - :LEU369 
:UNK - :VAL436 






:UNK:H9 - :THR364:O 
:LEU373:HD12 - :UNK 
:UNK - :LEU369 
:UNK - :MET440 
:UNK - :MET440 
*UNK = Ligand 
3.3 Molecular Dynamics Simulation 
The stability of the δ-3-carene and 5-lipoxygenase complex was assessed by 
molecular dynamics simulation (Figure 3). The backbone of both molecules 
could bend and move easily in the molecular dynamics process [33][34]. The 
simulation was performed for 20 ns at 310 K. 
The relationship between the RMSD value and the time length for the molecular 
dynamics ascertain the stability of the interactions between the ligand and 
Figure 3 The molecular dynamics visualization for the δ-3-
carene with 5-lipoxygenase complex. 
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receptor molecules. The molecular dynamics result was an RMSD value for the 
interaction between δ-3-carene and 5-lipoxygenase of less than 0.03nm (0.3Å) 
(Figure 4). This represents a stable complex structure [35]. The RMSF value 
indicates the atomic movement of the protein during the molecular dynamic 
simulation. In the RMSF graph, the atoms of the receptor that fluctuate more 
were the 1st atom (N of serine; RMSF 0.0388 nm), the 263rd atom (C of 
glycine; RMSF 0.0310nm), the 3045th atom (C of glycine; RMSF 0.0307nm), 
the 3430th atom (C of glycine; RMSF 0.0316nm), and the 4431st atom (C of 
glycine; RMSF 0.0309nm) (Figure 5). Potential energy illustrates the energy 
stability during a molecular dynamic simulation [14]. The graph of the potential 
energy complex of δ-3-carene with lipoxygenase showed energy stability during 
the simulation with a mean of -1.667392 x 106 kcal/mol (Figure 6). 
Figure 4 Graph of RMSD changes with time during the molecular dynamic 
simulation of δ-3-carene with 5-lipoxygenase complex. 
Figure 5 Graph of RMSF in the molecular dynamic simulations of δ-3-carene 
with 5-lipoxygenase complex. 
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4 Conclusion  
The compound in K. galanga L. that has the greatest affinity in inhibiting the 
enzyme 5-lipoxygenase (5-LOX) is δ-3-carene with the most negative 
ChemPLP value, -20.0002 kcal/mol. The binding affinity of δ-3-carene to the 5-
LOX receptor is higher than with zileuton as a reference ligand. The complex 
had good stability during the molecular dynamic simulation with an RMSD and 
RMSF value smaller than 3Å and -1.67392 x 106 kcal/mol for the mean of 
potential energy with a simulation time of 20ns. 
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